Case Investigations

GreenSky, Inc.

January 15, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of GreenSky, Inc. (“GreenSky” or the “Company”) (NASDAQ: GSKY).  GreenSky is a financial technology company that runs an online platform for processing loan applications at the point of sale.

AxoGen, Inc.

January 11, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of AxoGen, Inc. (“AxoGen” or the “Company”) (NASDAQ: AXGN), a company that purports to provide surgical solutions for physical damage or discontinuity to peripheral nerves.  AxoGen’s products include nerve allografts and extracellular matrices.  Investors who purchased AxoGen securities between August 7, 2017 and December 18, 2018, inclusive (the “Class Period”) may be affected.

Alkermes plc

January 8, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Alkermes plc (“Alkermes” or the “Company”) (NASDAQ: ALKS).  Investors who purchased Alkermes securities between February 17, 2017 and November 1, 2018, inclusive (the “Class Period”) may be affected.  A complaint has been filed in the United States District Court for the Eastern District of New York against Alkermes, the Company’s Chairman and CEO, and its CFO on behalf of investors of Alkermes securities during the Class Period.

Immunomedics Inc.

January 8, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors in Immunomedics, Inc. (“Immunomedics” or the “Company”) (NASDAQ: IMMU).  Investors who purchased Immunomedics common stock between August 23, 2018 and December 20, 2018, inclusive (the “Class Period”) may be affected.  A complaint has been filed in the United States District Court for the District of New Jersey against Immunomedics, the Company’s President and CEO, and its CFO on behalf of investors in Immunomedics common stock during the Class Period.

DXC Technology Company

January 8, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of DXC Technology Company (“DXC Technology” or the “Company”) (NYSE: DXC).  Investors who purchased DXC Technology common stock between February 8, 2018 and November 6, 2018, inclusive (the “Class Period”) may be affected.  A complaint has been filed in the United States District Court for the Eastern District of Virginia against DXC Technology,  J. Michael Lawrie, the Company’s CEO, and Paul N. Saleh, the Company’s CFO, on behalf of investors in DXC Technology common stock during the Class Period.

Perrigo Company plc

January 2, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors who purchased Perrigo Company plc (“Perrigo”) (NYSE: PRGO) securities.  Perrigo is a global healthcare company that is headquartered in Ireland, and sells its products primarily in North America and Europe, as well as in other markets, including Australia, Israel and China.

Nobilis Health Corp.

December 17, 2018 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors who purchased Nobilis Health Corp. (“Nobilis”) (NYSE American: HLTH) securities between May 8, 2018 and November 15, 2018 (the “Class Period”).  A complaint has been filed in the United States District Court for the Southern District of Texas against Nobilis, the Company’s CEO, and its former and current CFOs on behalf of investors of Nobilis securities during the Class Period.

Belden Inc.

December 13, 2018 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors who purchased Belden Inc. securities (“Belden” or the “Company”) (NYSE: BDC).

Cheetah Mobile Inc.

December 7, 2018 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Cheetah Mobile Inc. (“Cheetah” or the “Company”) (NYSE: CMCM).  Investors who purchased Cheetah securities between April 26, 2017 and November 27, 2018 (the “Class Period”) may be affected.  A complaint has been filed in the United States District Court for the Southern District of New York against Cheetah, the Company’s CEO, and its CFO on behalf of investors of Cheetah securities during the Class Period.

Aphria Inc.

December 4, 2018 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating Aphria Inc. (“Aphria” or the “Company”) (NYSE: APHA) concerning potential securities law violations.  Investors who purchased Aphria securities may be affected.

Marriott International, Inc.

November 30, 2018 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating Marriott International, Inc. (“Marriott” or the “Company”) (NASDAQ: MAR) concerning potential securities law violations.  Investors who purchased Marriott securities may be affected.

Goldman Sachs Group, Inc.

November 14, 2018 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Goldman Sachs Group, Inc. (“Goldman Sachs” or the “Company”) (NYSE: GS) concerning potential securities law violations.  Investors who purchased Goldman Sachs securities may be affected.

NiSource, Inc.

November 8, 2018 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of NiSource Inc. (“NiSource” or the “Company”) (NYSE: NI) concerning potential securities law violations.  Investors who purchased NiSource securities may be affected.

Super Micro Computer, Inc.

October 4, 2018 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating Super Micro Computer, Inc. (“Super Micro” or the “Company”) (OTC: SMCI) concerning potential securities law violations.  Investors who purchased Super Micro securities may be affected.

 

Geron Corporation

September 27, 2018 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors of Menlo park, California-based Geron Corporation (“Geron” or the “Company”) (Nasdaq: GERN).

Chegg, Inc.

September 26, 2018 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors of Santa Clara, California-based Chegg, Inc. (“Chegg” or the “Company”) (NYSE: CHGG).

Microchip Technology, Inc.

September 20, 2018 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Microchip Technology Inc. (“Microchip” or the “Company”) (NASDAQ: MCHP).  Investors who purchased Microchip common stock between March 2, 2018 and August 9, 2018 (the “Class Period”) may be affected.  A complaint has been filed in the United States District Court for the District of Arizona against Microchip and certain executives on behalf of investors that acquired Microchip common stock during the Class Period.

AbbVie, Inc.

September 18, 2018 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors of AbbVie Inc. (“AbbVie” or the “Company”).

USA Technologies, Inc.

September 11, 2018 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors of USA Technologies, Inc. (“USA Technologies” or the “Company”), which is based in Malverne, Pennsylvania (Nasdaq: USAT).

CV Sciences, Inc.

September 6, 2018 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of CV Sciences, Inc. (“CV Sciences” or the “Company”) (OTC: CVSI).  Investors who purchased CV Sciences common stock between June 19, 2017 and August 20, 2018 (the “Class Period”) may be affected.  A complaint has been filed in the United States District Court for the District of Nevada against CV Sciences and certain executives on behalf of investors that acquired CV Sciences common stock during the Class Period.

CBS Corporation

September 6, 2018 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of CBS Corporation (“CBS” or the “Company”) (NYSE: CBS).  Investors who purchased CBS securities between February 14, 2014 and July 27, 2018 (the “Class Period”) may be affected.  A complaint has been filed in the United States District Court for the Southern District of New York against CBS and certain executives on behalf of investors that acquired CBS securities during the Class Period.

Nevro Corporation

September 6, 2018 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Nevro Corporation (“Nevro” or the “Company”) (NYSE: NVRO).  Investors who purchased Nevro common stock between January 8, 2018 and July 12, 2018 (the “Class Period”) may be affected.  A complaint has been filed in the United States District Court for the Northern District of California against Nevro and certain executives on behalf of investors that acquired Nevro common stock during the Class Period.

Impinj, Inc.

August 22, 2018 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Impinj, Inc. (“Impinj” or the “Company”) (NASDAQ: PI).  Investors who purchased Impinj securities between May 7, 2018 and August 2, 2018 (the “Class Period”) may be affected.  A complaint has been filed in the United States District Court for the Central District of California against Impinj and certain executives on behalf of investors that acquired Impinj securities during the Class Period.

Sinclair Broadcast Group, Inc.

August 10, 2018 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Sinclair Broadcast Group, Inc. (“Sinclair” or the “Company”) (NASDAQ: SBGI).  Investors who purchased Sinclair securities between February 22, 2017 and July 19, 2018 (the “Class Period”) may be affected.  A complaint has been filed in the United States District Court for the District of Maryland against Sinclair and certain executives of the Company on behalf of investors that purchased or otherwise acquired Sinclair common stock during the Class Period.

Tesla, Inc.

August 9, 2018 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating Tesla, Inc. (“Tesla” or the “Company”) (NASDAQ: TSLA) concerning potential securities law violations.  Investors who purchased Tesla securities may be affected.

Ampio Pharmaceuticals, Inc.

August 8, 2018 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) (NYSE: AMPE) concerning potential securities law violations.  Investors who purchased Ampio securities may be affected.

GDS Holdings Limited

August 1, 2018 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating GDS Holdings Limited (“GDS” or the “Company”) (NASDAQ: GDS) concerning potential securities law violations.  Investors who purchased GDS American Depositary Shares, or “ADSs” that trade under the symbol GDS may be affected.

ACADIA Pharmaceuticals Inc.

August 1, 2018 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. (“ACADIA” or the “Company”) (Nasdaq: ACAD).  Investors who purchased ACADIA securities between April 29, 2016 and July 9, 2018 (the “Class Period”) may be affected.  A complaint has been filed in the United States District Court, Southern District of California against ACADIA and certain executives on behalf of investors that acquired ACADIA securities during the Class Period.

Farmland Partners Inc.

July 24, 2018 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Farmland Partners Inc. (“Farmland” or the “Company”) (NYSE: FPI).  Investors who purchased Farmland securities between May 9, 2017 and July 10, 2018 (the “Class Period”) may be affected.

Prothena Corporation plc

July 24, 2018 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Prothena Corporation plc (“Prothena” or the “Company”) (NASDAQ: PRTA).  Investors who purchased Prothena common stock between October 15, 2015 and April 20, 2018 (the “Class Period”) may be affected.  A Class Action has been filed against Prothena and certain current and former Company executives on behalf of investors who purchased Prothena’s publicly traded common stock during the Class Period.